🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by TikTok fitness influencers and vendors on messaging platforms, based on new investigations.

Experimental Treatment Acquiring Popularity Online

The experimental drug, which remains in research studies, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are encouraged to message these profiles directly for source information, while also receiving promotional offers.

Active Trade on Social Networks

Additionally, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and claims of next-day British shipping. Sellers market the drug there before redirecting customers to other platforms for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Medical Professionals Express Worries

However, doctors and pharmacists have warned that the distribution of what is still an unlicensed medication in the UK is worrisome and could lead to individuals injecting products of unknown origin.

Some experts said the popularity for retatrutide could be connected to the rising price of licensed weight loss treatments such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach pharmaceutical, advertising, and customer laws, risking fines, legal action or imprisonment.

Service Response and Content Removal

According to TikTok, the service has removed problematic content and banned associated hashtags and search suggestions. The company stated it was committed to keeping the service safe and allocating resources in strengthening compliance measures.

Digital Trading Operations

Research also discovered groups with up to 9,000 participants selling the experimental drug using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of members, populated with images of weight loss, positive reviews and step-by-step guides for preparing or injecting at residence.

After minutes of entering one community, a vendor posted contact information, where the majority of transactions take place. The seller sent an instruction manual and guaranteed delivery within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. Not one inquired about body mass, health issues or past usage.

Product Details and Costs

Inside these communities, messages show black plastic packages with Royal Mail labels, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually priced at 160 pounds for 20 milligrams. When asked how long a pen should be used, sellers give conflicting answers varying between a several days to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for Telegram said it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they can’t verify. Although the science behind this drug is valid, these digital versions may not include what they claim,” said Jason Murphy, the director of pharmacy at Chemist4U.

A medical professional of an online medical service linked the surge in demand to recent cost increases for authorized weight-loss medications such as Mounjaro. “With costs increasing, individuals are turning to social media. But fake treatments are extremely dangerous. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her staff has previously seen individuals harmed by self-injection from unconfirmed suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” stated the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this point no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may subject users to potentially serious medical dangers”.